Skip to main content

Research Repository

Advanced Search

All Outputs (16)

Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model: a clinical and laboratory case report. (2024)
Journal Article
GOODARZI, S., ABU-HANNA, J., HARPER, S., KHAN, D., MORROW, G. and CURRY, N. 2024. Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model: a clinical and laboratory case report. Frontiers in medicine [online], 11, article 1391422. Available from: https://doi.org/10.3389/fmed.2024.1391422

The choice of treatments for inherited, or acquired, fibrinogen deficient states is expanding and there are now several fibrinogen concentrate therapies commercially available. Patients with the rare inherited bleeding disorder, afibrinogenemia, comm... Read More about Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model: a clinical and laboratory case report..

A novel method to quantify fibrin-fibrin and fibrin-α2AP cross-links in thrombi formed from human trauma patient plasma. (2024)
Journal Article
MORROW, G.B., FLANNERY, S., CHARLES, P.D., HEILIG, R., FELLER, T., MCQUILTEN, Z., WAKE, E., ARIENS, R.A.S., WINEARLS, J., MUTCH, N.J., FISCHER, R., LAFFAN, M.A. and CURRY, N. [2024]. A novel method to quantify fibrin-fibrin and fibrin-α2AP cross-links in thrombi formed from human trauma patient plasma. Journal of thrombosis and haemostasis [online], Articles in Press. Available from: https://doi.org/10.1016/j.jtha.2024.03.001

The widespread use of the anti-fibrinolytic agent, tranexamic acid (TXA), interferes with the quantification of fibrinolysis by dynamic laboratory assays such as clot lysis, making it difficult to measure fibrinolysis in many trauma patients. At the... Read More about A novel method to quantify fibrin-fibrin and fibrin-α2AP cross-links in thrombi formed from human trauma patient plasma..

Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting. (2023)
Journal Article
WHYTE, C.S., MORROW, G.B., GAUER, J.S., MONTAGUE, S.J. and NICOLSON, P.L.R. 2023. Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting (BSHT2023), 25-27 January 2023, Birmingham, UK. Front in cardiovascular medicine [online], 10, article number 1225243. Available from: https://doi.org/10.3389/fcvm.2023.1225243

The BSHT held its annual meeting between January 25th and 27th 2023 at the Edgbaston Park Hotel & Conference Centre, Birmingham, United Kingdom. The meeting is an opportunity for academic researchers, biomedical scientists and clinicians to network a... Read More about Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British Society for Haemostasis and Thrombosis annual meeting..

Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability. (2023)
Journal Article
MITCHELL, J.L., LITTLE, G., BYE, A.P. et al. 2023. Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability. Research and practice in thrombosis and haemostasis [online], 7(5), article 100200. Available from: https://doi.org/10.1016/j.rpth.2023.100200

Factor XIII (FXIII) is an important proenzyme in the hemostatic system. The plasma-derived enzyme activated FXIII cross-links fibrin fibers within thrombi to increase their mechanical strength and cross-links fibrin to fibrinolytic inhibitors, specif... Read More about Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability..

Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2023. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Seminars in thrombosis and hemostasis [online], 49(3), pages 305-313. Available from: https://doi.org/10.1055/s-0042-1758791

Plasminogen activator inhibitor 1 (PAI-1), a SERPIN inhibitor, is primarily known for its regulation of fibrinolysis. However, it is now known that this inhibitor functions and contributes to many (patho)physiological processes including inflammation... Read More about Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1)..

The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. (2022)
Journal Article
WHYTE, C.S., SIMPSON, M., MORROW, G.B., WALLACE, C.A., MENTZER, A.J., KNIGHT, J.C., SHAPIRO, S., CURRY, N., BAGOT, C.N., WATSON, H., COOPER, J.G. and MUTCH, N.J. 2022. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of thrombosis and haemostasis [online], 20(10), pages 2394-2406. Available from: https://doi.org/10.1111/jth.15806

Severe COVID-19 disease is associated with thrombotic complications and extensive fibrin deposition. This study investigates whether the hemostatic complications in COVID-19 disease arise due to dysregulation of the fibrinolytic system. This prospect... Read More about The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1..

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. (2022)
Journal Article
MORROW, G.B., FELLER, T., MCQUILTEN, Z., WAKE, E., ARIËNS, R.A.S., WINEARLS, J., MUTCH, N.J., LAFFAN, M.A. and CURRY, N. 2022. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial. Critical care [online], 26, article number 290. Available from: https://doi.org/10.1186/s13054-022-04167-x

Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT... Read More about Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: results from a laboratory sub-study of the FEISTY trial..

Removing plasmin from the equation: something to chew on… (2022)
Journal Article
MORROW, G.B. and MUTCH, N.J. 2022. Removing plasmin from the equation: something to chew on… Journal of thrombosis and haemostasis [online], 20(2), pages 280-284. Available from: https://doi.org/10.1111/jth.15590

Thrombolytics or fibrinolytics are a group of pharmacological agents used to target and dissolve occlusive intravascular thrombi. Thrombi form a haemostatic plug at the site of injury to arrest bleeding and are essential for wound healing. However, i... Read More about Removing plasmin from the equation: something to chew on….

A serpin with a finger in many PAIs: PAI-1’s central function in thromboinflammation and cardiovascular disease. (2021)
Journal Article
MORROW, G.B., WHYTE, C.S. and MUTCH, N.J. 2021. A serpin with a finger in many PAIs: PAI-1’s central function in thromboinflammation and cardiovascular disease. Frontiers in cardiovascular medicine [online], 8, article 653655. Available from: https://doi.org/10.3389/fcvm.2021.653655

Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA), and urokinase-type plasminogen activator... Read More about A serpin with a finger in many PAIs: PAI-1’s central function in thromboinflammation and cardiovascular disease..

Fibrinogen replacement therapy for traumatic coagulopathy: does the fibrinogen source matter? (2021)
Journal Article
MORROW, G.B., CARLIER, M.S.A., DASGUPTA, S., CRAIGEN, F.B., MUTCH, M.J. and CURRY, N. 2021. Fibrinogen replacement therapy for traumatic coagulopathy: does the fibrinogen source matter? International journal of molecular sciences [online], 22(4), article 2185. Available from: https://doi.org/10.3390/ijms22042185

Fibrinogen is the first coagulation protein to reach critically low levels during traumatic haemorrhage. There have been no differential effects on clinical outcomes between the two main sources of fibrinogen replacement: cryoprecipitate and fibrinog... Read More about Fibrinogen replacement therapy for traumatic coagulopathy: does the fibrinogen source matter?.

Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype. (2020)
Journal Article
MORROW, G.B., BEAVIS, J., HARPER, S., BIGNELL, P., LAFFAN, M.A. and CURRY, N. 2021. Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype. Thrombosis research [online], 197, pages 100-108. Available from: https://doi.org/10.1016/j.thromres.2020.11.002

A novel variant in the thrombomodulin (TM) gene, c.1487delC,p.(Pro496Argfs*10), referred to as Pro496Argfs*10, was identified in a family with an unexplained bleeding disorder. The Pro496Argfs*10 variant results in loss of the transmembrane and intra... Read More about Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype..

Exposure of plasminogen and a novel plasminogen receptor, Plg-RKT, on activated human and murine platelets. (2020)
Journal Article
WHYTE, C.S., MORROW, G.B., BAIK, N., BOOTH, N.A., JALAL, M.M., PARR, R.J. and MUTCH, N.J. 2021. Exposure of plasminogen and a novel plasminogen receptor, Plg-RKT, on activated human and murine platelets. Blood [online], 137(2), pages 248-257. Available from: https://doi.org/10.1182/blood.2020007263

Plasminogen activation rates are enhanced by cell surface binding. We previously demonstrated that exogenous plasminogen binds to phosphatidylserine-exposing and spread platelets. Platelets contain plasminogen in their α-granules, but secretion of pl... Read More about Exposure of plasminogen and a novel plasminogen receptor, Plg-RKT, on activated human and murine platelets..

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. (2020)
Journal Article
WHYTE, C.S., MORROW, G.B., MITCHELL, J.L., CHOWDARY, P. and MUTCH, N.J. 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. Journal of thrombosis and haemostasis [online], 18(7), pages 1548-1555. Available from: https://doi.org/10.1111/jth.14872

The global pandemic of coronavirus disease 2019 (COVID‐19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflamm... Read More about Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19..

Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. (2020)
Journal Article
MORROW, G.B., BEAVIS, J., HARPER, S., BAKER, P., DESBOROUGH, M.J.R., CURRY, N., STANWORTH, S.J. and LAFFAN, M.A. 2020. Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. Journal of thrombosis and haemostasis [online], 18(7), pages 1576-1585. Available from: https://doi.org/10.1111/jth.14802

The liver synthesizes the majority of pro- and anti-oagulant and fibrinolytic proteins, and during liver dysfunction synthesis of these proteins is reduced. The end point of conventional hemostatic tests, such as the prothrombin time (PT), occurs whe... Read More about Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer..

Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation. (2019)
Journal Article
MORROW, G.B., WHYTE, C.S. and MUTCH, N.J. 2020. Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation. Haematologica [online], 105(12), pages 2824-2833. Available from: https://doi.org/10.3324/haematol.2019.230367

Platelets harbor the primary reservoir of circulating plasminogen activator inhibitor 1 (PAI-1), but the reportedly low functional activity of this pool of inhibitor has led to debate over its contribution to thrombus stability. Here we analyze the f... Read More about Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation..

UTP is not a biased agonist at human P2Y11 receptors. (2014)
Journal Article
MORROW, G.B., NICHOLAS, R.A. and KENNEDY, C. 2014. UTP is not a biased agonist at human P2Y11 receptors. Purinergic signalling [online], 10(4), pages 581-585. Available from: https://doi.org/10.1007/s11302-014-9418-3

Biased agonism describes a multistate model of G protein-coupled receptor activation in which each ligand induces a unique structural conformation of the receptor, such that the receptor couples differentially to G proteins and other intracellular pr... Read More about UTP is not a biased agonist at human P2Y11 receptors..